TP53 and bladder transitional cell carcinoma: As was showed in Figure 13 and Table 2, Mitomycin-C had a significant increased sensitivity in TP53 mutation (P = 0.000322) of BLCA patients and the IC50 of Mitomycin-C was significant decreased in TP53 mutation group (P = 0.001).